Literature DB >> 15298723

ETS transcription factors: possible targets for cancer therapy.

Tsuneyuki Oikawa1.   

Abstract

Ets family (ETS) transcription factors, characterized by an evolutionally conserved Ets domain, play important roles in cell development, cell differentiation, cell proliferation, apoptosis and tissue remodeling. Most of them are downstream nuclear targets of Ras-MAP kinase signaling, and the deregulation of ETS genes results in the malignant transformation of cells. Several ETS genes are rearranged in human leukemia and Ewing tumors to produce chimeric oncoproteins. Furthermore, the aberrant expression of several ETS genes is often observed in various types of human malignant tumors. Considering that some ETS transcription factors are involved in malignant transformation and tumor progression, including invasion, metastasis and neo-angiogenesis through the activation of cancer-related genes, they could be potential molecular targets for selective cancer therapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15298723     DOI: 10.1111/j.1349-7006.2004.tb03320.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  66 in total

1.  Quantitative Investigation of Protein-Nucleic Acid Interactions by Biosensor Surface Plasmon Resonance.

Authors:  Shuo Wang; Gregory M K Poon; W David Wilson
Journal:  Methods Mol Biol       Date:  2015

2.  A computational framework for the topological analysis and targeted disruption of signal transduction networks.

Authors:  Madhukar S Dasika; Anthony Burgard; Costas D Maranas
Journal:  Biophys J       Date:  2006-04-14       Impact factor: 4.033

3.  Downregulation of Friend leukemia virus integration 1 as a feedback mechanism that restrains lipopolysaccharide induction of matrix metalloproteases and interleukin-10 in human macrophages.

Authors:  Hao H Ho; Lionel B Ivashkiv
Journal:  J Interferon Cytokine Res       Date:  2010-09-29       Impact factor: 2.607

4.  Correlated motions and interactions at the onset of the DNA-induced partial unfolding of Ets-1.

Authors:  Hiqmet Kamberaj; Arjan van der Vaart
Journal:  Biophys J       Date:  2009-02-18       Impact factor: 4.033

5.  Lipopolysaccharide-induced expression of matrix metalloproteinases in human monocytes is suppressed by IFN-gamma via superinduction of ATF-3 and suppression of AP-1.

Authors:  Hao H Ho; Taras T Antoniv; Jong-Dae Ji; Lionel B Ivashkiv
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

6.  The ETS protein MEF is regulated by phosphorylation-dependent proteolysis via the protein-ubiquitin ligase SCFSkp2.

Authors:  Yan Liu; Cyrus V Hedvat; Shifeng Mao; Xin-Hua Zhu; Jinjuan Yao; Hoang Nguyen; Andrew Koff; Stephen D Nimer
Journal:  Mol Cell Biol       Date:  2006-04       Impact factor: 4.272

7.  Identifying candidate Hirschsprung disease-associated RET variants.

Authors:  Grzegorz M Burzynski; Ilja M Nolte; Agnes Bronda; Krista K Bos; Jan Osinga; Ivan Plaza Menacho; Bas Twigt; Saskia Maas; Alice S Brooks; Joke B G M Verheij; Charles H C M Buys; Robert M W Hofstra
Journal:  Am J Hum Genet       Date:  2005-03-09       Impact factor: 11.025

8.  Overexpression of ETS-1 is associated with malignant biological features of prostate cancer.

Authors:  Bo Li; Yosuke Shimizu; Takashi Kobayashi; Naoki Terada; Koji Yoshimura; Tomomi Kamba; Yoshiki Mikami; Takahiro Inoue; Hiroyuki Nishiyama; Osamu Ogawa
Journal:  Asian J Androl       Date:  2012-10-15       Impact factor: 3.285

9.  Inhibition of invasion-associated thromboxane synthase sensitizes experimental gliomas to gamma-radiation.

Authors:  Anne Katrin Schauff; Ella L Kim; Jan Leppert; Roger Nadrowitz; Robin Wuestenberg; Mark Alexander Brockmann; Alf Giese
Journal:  J Neurooncol       Date:  2008-09-30       Impact factor: 4.130

10.  Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.

Authors:  Jessica Kao; Keyan Salari; Melanie Bocanegra; Yoon-La Choi; Luc Girard; Jeet Gandhi; Kevin A Kwei; Tina Hernandez-Boussard; Pei Wang; Adi F Gazdar; John D Minna; Jonathan R Pollack
Journal:  PLoS One       Date:  2009-07-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.